InBioGen Co Ltd (101140) - Total Assets
Based on the latest financial reports, InBioGen Co Ltd (101140) holds total assets worth ₩173.22 Billion KRW (≈ $117.39 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can InBioGen Co Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
InBioGen Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how InBioGen Co Ltd's total assets have evolved over time, based on quarterly financial data. See InBioGen Co Ltd book value and equity for net asset value and shareholders' equity analysis.
InBioGen Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
InBioGen Co Ltd's total assets of ₩173.22 Billion consist of 5.7% current assets and 94.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.5% |
| Accounts Receivable | ₩3.29 Billion | 2.0% |
| Inventory | ₩111.03 Million | 0.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩190.82 Million | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how InBioGen Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is InBioGen Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InBioGen Co Ltd's current assets represent 5.7% of total assets in 2024, a decrease from 97.6% in 2013.
- Cash Position: Cash and equivalents constituted 3.5% of total assets in 2024, down from 10.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
InBioGen Co Ltd Competitors by Total Assets
Key competitors of InBioGen Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Birkenstock Holding plc
NYSE:BIRK
|
USA | $5.17 Billion |
|
PUMA SE
XETRA:PUM
|
Germany | €7.06 Billion |
|
Topscore Fashion
SHG:603608
|
China | CN¥1.49 Billion |
|
Anhui Korrun Co Ltd
SHE:300577
|
China | CN¥6.10 Billion |
|
Alpargatas S.A
SA:ALPA3
|
Brazil | R$6.29 Billion |
|
Fulgent Sun International Holding Co Ltd
TW:9802
|
Taiwan | NT$22.15 Billion |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
China | CN¥3.53 Billion |
|
Sanwil Holding SA
WAR:SNW
|
Poland | zł77.60 Million |
InBioGen Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 4.18 | 4.73 |
| Quick Ratio | 2.94 | 3.95 | 4.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩3.69 Billion | ₩6.48 Billion | ₩67.71 Billion |
InBioGen Co Ltd - Advanced Valuation Insights
This section examines the relationship between InBioGen Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | ₩162.73 Billion |
| Market Capitalization | $36.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values InBioGen Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: InBioGen Co Ltd's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for InBioGen Co Ltd (2013–2024)
The table below shows the annual total assets of InBioGen Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩162.73 Billion ≈ $110.28 Million |
+7.55% |
| 2023-12-31 | ₩151.31 Billion ≈ $102.54 Million |
+6.69% |
| 2022-12-31 | ₩141.81 Billion ≈ $96.11 Million |
-48.33% |
| 2021-12-31 | ₩274.47 Billion ≈ $186.01 Million |
+183.31% |
| 2020-12-31 | ₩96.88 Billion ≈ $65.65 Million |
+6.56% |
| 2019-12-31 | ₩90.92 Billion ≈ $61.61 Million |
+273.83% |
| 2018-12-31 | ₩24.32 Billion ≈ $16.48 Million |
+81.64% |
| 2017-12-31 | ₩13.39 Billion ≈ $9.07 Million |
+8.19% |
| 2016-12-31 | ₩12.38 Billion ≈ $8.39 Million |
-15.00% |
| 2015-12-31 | ₩14.56 Billion ≈ $9.87 Million |
+104.77% |
| 2014-12-31 | ₩7.11 Billion ≈ $4.82 Million |
-28.93% |
| 2013-12-31 | ₩10.00 Billion ≈ $6.78 Million |
-- |
About InBioGen Co Ltd
INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.